Therefore, this study aimed to broaden the knowledge on the role of the CRNDE gene and its protein product, CRNDEP, in ovarian tumors of different aggressiveness, i.e., the most aggressive high-grade ovarian carcinomas (hgOvCa), borderline ovarian tumors (BOTS) without (BOT) and with the BRAF V600E mutation (BOT V600E), and low-grade ovarian carcinomas (lgOvCa). Here, BRAF is linked to ovarian carcinoma.